Lexaria's DehydraTECH-CBD diabetes study shows weight loss, improved triglycerides and cholesterol in obese rats

Lexaria Bioscience Corp.

7% body weight loss maintained over 8 weeks in obese diabetic Zucker rats dosed with DehydraTECH-CBD.
Triglyceride levels over 25% lower at 30 mg/Kg dose vs untreated obese rats (p=0.007).
Lower dose (30 mg/Kg) improved HDL cholesterol without significant effect on LDL; higher dose increased both.
Lower dose significantly improved locomotor activity (p<0.05) compared to untreated obese controls.
Study DIAB-A22-1 conducted by third-party lab in Canada over 8 weeks; no serious health concerns observed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.